Strategies to improve adherence with medications in chronic, ‘silent’ diseases representing high cardiovascular risk

References

• Bartels D. Adherence to oral therapy for Type 2 diabetes: opportunities for enhancing glycemic control. J. Am. Acad. Nurse Pract.16(1), 8–16 (2004).
   Google Scholar
• Stratton IM, Adler AI, Neil HA et al. Association of glycaemia with macrovascular and microvascular complications of Type 2 diabetes (UKPDS 35): Prospective observational study. Br. Med. J.321, 405–412 (2000).
   PubMed Web of Science ®Google Scholar
• Perreault S, Blais L, Lamarre D et al. Persistence and determinants of statin therapy among middle-aged patients for primary and secondary prevention. Br. J. Clin. Pharmacol.59(5), 564–573 (2005).
   PubMed Web of Science ®Google Scholar
• Kearney PM, Whelton M, Reynolds K et al. Worldwide prevalence of hypertension: a systematic review. J. Hypertens.22, 11–19 (2004).
   PubMed Web of Science ®Google Scholar
• McInnes GT. How important is optimal blood pressure control? Clin. Ther.26(Suppl. A), A3–A11 (2004).
   Web of Science ®Google Scholar
• National Heart, Lung, and Blood Institute. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. US Department of Health and Human Services, Washington DC, USA, NIH Publication No. 04–5230 (2004).
   Google Scholar
• Lawes CMM, Vander Hoorn S, Law MR, Elliott P, MacMahon S, Rodgers A. High blood pressure. In: Comparative Quantification of Health Risks: Global and Regional Burden of Disease Attributable to Selected Major Risk Factors. Volume 1. Ezzati M, Lopez AD, Rodger A, Murray CJL (Eds). WHO, Geneva, Switzerland, 281–389 (2004).
   Google Scholar
• Flack JM, Casciano R, Casciano J et al. Cardiovascular disease costs associated with uncontrolled hypertension. Manag. Care Interface15, 28–36 (2002).
   PubMedGoogle Scholar
• EUROASPIRE I and II Group. European Action on Secondary Prevention by Intervention to Reduce Events. EUROASPIRE I and II Group Clinical reality of coronary prevention guidelines: a comparison of EUROASPIRE I and II in nine countries. Lancet357, 995–1001 (2001).
   PubMed Web of Science ®Google Scholar
• Frolkis JP, Pearce GL, Nambi V et al. Statins do not meet expectations for lowering low-density lipoprotein cholesterol levels when used in clinical practice. Am. J. Med.113, 625–629 (2002).
   PubMed Web of Science ®Google Scholar
• Goodall T, Halford W. Self-management of diabetes mellitus: a critical review. Health Psychol.10, 1–8 (1991).
   PubMed Web of Science ®Google Scholar
• Blanford L et al. Analyzing variations in medication compliance related to individual drug, drug class, and prescribing physician. JMCP5, 47–51 (1999).
   Google Scholar
• Steiner JF, Prochazka AV. The assessment of refill compliance using pharmacy records: methods, validity, and applications. J. Clin. Epidemiol.50(1), 105–116 (1997).
   PubMed Web of Science ®Google Scholar
• Sikka R, Xia F, Aubert RE. Estimating medication persistency using administrative claims data. Am. J. Manag. Care11, 449–457 (2005).
   PubMed Web of Science ®Google Scholar
• Schneider M, Burner M. Treatment adherence and hypertension management. In: Advanced Therapy in Hypertension and Vascular Disease. Mohler III ER, Townsend RR (Eds), Elsevier, NY, USA, 604–613 (2006).
   Google Scholar
• Halpern MT, Khan ZM, Schmier JK et al. Recommendations for evaluating compliance and persistence with hypertension therapy using retrospective data. Hypertension47(6), 1039–1048 (2006).
   PubMed Web of Science ®Google Scholar
• Burnier M, Hess B, Greminger P, Waeber B. Determinants of persistence in hypertensive patients treated with irbesartan: results of a postmarketing survey. BMC Cardiovasc. Disord.5, 13 (2005).
   PubMedGoogle Scholar
• Düsing R, Weisser B, Mengden T, Vetter H. Changes in antihypertensive therapy – the role of adverse effects and compliance. Blood Pressure7, 313–315 (1998).
   PubMedGoogle Scholar
• Morris AD. Addressing dosing frequency in diabetes: a simple approach to improving adherence to therapy and clinical outcomes. Diabetes Educ.29(3), 440–453 (2003).
   PubMed Web of Science ®Google Scholar
• Iskedjian M, Einarson TR, MacKeigan LD et al. Relationship between daily dose frequency and adherence to antihypertensive pharmacotherapy: evidence from a meta-analysis. Clin. Ther.24, 302–316 (2002).
   PubMed Web of Science ®Google Scholar
• Cramer JA. A systematic review of adherence with medications for diabetes. Diabetes Care27(5), 1218–1224 (2004).
   PubMed Web of Science ®Google Scholar
• Claxton AJ Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin. Ther.23(8), 1296–1310 (2001).
   PubMed Web of Science ®Google Scholar
• Gerth WC. Compliance and persistence with newer antihypertensive agents. Curr. Hypertens. Rep.4(6), 424–433 (2002).
   PubMed Web of Science ®Google Scholar
• Peterson AM, Takiya L, Finley R. Meta-analysis of interventions to improve drug adherence in patients with hyperlipidemia. Pharmacotherapy23(1), 80–87 (2003).
   Google Scholar
• Monane M, Bohn RL, Gurwitz JH et al. The effects of initial drug choice and comorbidity on antihypertensive therapy compliance: results from a population-based study in the elderly. Am. J. Hypertens.10, 697–704 (1997).
   PubMed Web of Science ®Google Scholar
• Erkens JA, Panneman MMJ, Klungel OH, Boom G, Prescott MF, Herings RMC. Differences in antihypertensive drug persistence associated with drug class and gender: a PHARMO study. Pharmacoepidemiol. Drug Saf.14, 795–803 (2005).
   PubMed Web of Science ®Google Scholar
• Wang PS, Bohn RL, Knight E et al. Noncompliance with antihypertension medications: the impact of depressive symptoms and psychosocial factors. J. Gen. Intern. Med.17, 504–511 (2002).
   PubMed Web of Science ®Google Scholar
• Redon J. Hypertension in obesity. Nutr. Metab. Cardiovasc. Dis.11, 344–353 (2001).
   PubMed Web of Science ®Google Scholar
• Goldman DP, Joyce GF, Escarce JJ et al. Pharmacy benefits and the use of drugs by the chronically ill. JAMA291, 2344–2350 (2004).
   PubMed Web of Science ®Google Scholar
• Rubin RR. Adherence to pharmacologic therapy in patients with Type 2 diabetes mellitus. Am. J. Med.118(5A), 27S–34S (2005).
   PubMed Web of Science ®Google Scholar
• Peltzer K. Health beliefs and prescription medication compliance among diagnosed hypertension clinic attenders in a rural South African hospital. Curationis27, 15–23 (2004).
   PubMedGoogle Scholar
• Wetzels GEC, Nelemans P, Schouten JS, Prins MH. Facts and fiction of poor compliance as a cause of inadequate blood pressure control: a systematic review. J. Hypertens.22, 1849–1855 (2004).
   PubMed Web of Science ®Google Scholar
• Riesen WF, Darioli R, Noll G. Lipid-lowering therapy: strategies for improving compliance. Curr. Med. Res. Opin.20(2), 165–173 (2004).
   PubMed Web of Science ®Google Scholar
• Roter DL, Hall JA, Merisca R et al. Effectiveness of interventions to improve patient compliance: a meta-analysis. Medical Care36(8), 1138–1161 (1998).
   PubMed Web of Science ®Google Scholar
• Takiya LN, Peterson AM, Finley RS. Meta-analysis of interventions for medication adherence to antihypertensives. Ann. Pharmacother.38, 1617–1624 (2004).
   PubMed Web of Science ®Google Scholar
• Schroeder K, Fahey T, Ebrahim S. How can we improve adherence to blood pressure-lowering medication in ambulatory care? Systematic review of randomized controlled trials. Arch. Intern. Med.164, 722–732 (2004).
   PubMed Web of Science ®Google Scholar
• Hunt JS, Siemienczuk J, Touchette D, Payne N. Impact of educational mailing on the blood pressure of primary care patients with mild hypertension. J. Gen. Intern. Med.19, 925–930 (2004).
   Google Scholar
• Louis-Simonet M, Kossovsky MP, Sarasin FP et al. Effects of structured patient-centered discharge interview on patients’ knowledge about their medications. Am. J. Med.117, 563–568 (2004).
   Google Scholar
• Morrison A, Wertheimer AI, Berger ML. Interventions to improve antihypertensive drug adherence: a quantitative review of trials. Formulary35, 234–255 (2000).
   Web of Science ®Google Scholar
• Dailey G, Kim MS, Lian JF. Patient compliance and persistence with antihyperglycemic drug regimens: evaluations of a Medicaid population with Type 2 diabetes mellitus. Clin. Ther.23(8), 1311–1320 (2001).
   PubMed Web of Science ®Google Scholar
• Melikian C, White J, Vanderplas A et al. Adherence to oral antidiabetic therapy in a managed care organization: a comparison of monotherapy, combination therapy, and fixed-dose combination therapy. Clin. Ther.24(3), 460–467 (2002).
   PubMed Web of Science ®Google Scholar
• Morris AD, Brennan GM, Macdonald T et al. Population-based adherence to prescribed medication in Type 2 diabetes: a cause for concern. Diabetes.49(Suppl. 1), A76 (2000).
   Web of Science ®Google Scholar
• Garber A, Jaime D, Mooradian A et al. Effect of metformin/glyburide tablets on HbA1c in first-line treatment of Type 2 diabetes. Diabetes.49(Suppl. 1), A107 (2000).
   Google Scholar
• Fujioka K, Pans M, Joyal S. Glycemic control in patients with Type 2 diabetes mellitus switched from twice-daily immediate-release metformin to a once-daily extended-release formulation. Clin. Ther.25(2), 515–529 (2003).
   PubMed Web of Science ®Google Scholar
• Leenen FH, Wilson TW, Bolli P et al. Patterns of compliance with once versus twice daily antihypertensive drug therapy in primary care: a randomized clinical trial using electronic monitoring. Can. J. Cardiol.13(10), 914–920 (1997).
   PubMed Web of Science ®Google Scholar
• Brown GB, Bardsley J, Poulin D et al. Moderate dose, three-drug therapy with niacin, lovastatin, and colestipol to reduce low-density lipoprotein cholesterol <100 mg/dl in patients with hyperlipidemia and coronary artery disease. Am. J. Cardiol.80, 111–115 (1997).
   PubMed Web of Science ®Google Scholar
• Rosen MI, Rigsby MO, Salahi JT et al. Electronic monitoring and counseling to improve medication adherence. Behav. Res. Ther.42, 409–422 (2004).
   PubMed Web of Science ®Google Scholar
• Skaer TL, Sclar DA, Markowski DJ, Won JK. Effect of value-added utilities on prescription refill compliance and health care expenditures for hypertension. J. Hum. Hypertens.7(5), 515–518 (1993).
   PubMed Web of Science ®Google Scholar
• Guthrie RM. The effects of postal and telephone reminders on compliance with pravastatin therapy in a national registry: results of the first myocardial infarction risk reduction program. Clin. Ther.23(6), 970–980 (2001).
   PubMed Web of Science ®Google Scholar
• Simmons D, Upjohn M, Gamble GD. Can medication packaging improve glycemic control and blood pressure in type 2 diabetes? Diabetes Care23(2), 153–156 (2000).
   Google Scholar
• Edmonds D, Foerster E, GrothH et al. Does self-measurement of blood pressure improve patient compliance in hypertension? J. Hypertens. (Suppl. 3), 31–34 (1985).
   Google Scholar
• Zarnke KB, Feagan BG, Mahon JL et al. A randomized study comparing a patient-directed hypertension management strategy with usual office-based care. Am. J. Hypertens.10, 58–67 (1997).
   PubMed Web of Science ®Google Scholar
• Mehos BM, Saseen JJ, MacLaughlin EJ. Effect of pharmacist intervention and initiation of home blood pressure monitoring in patients with uncontrolled hypertension. Pharmacotherapy20(11), 1384–1389 (2000).
   PubMed Web of Science ®Google Scholar
• Davidson J. Strategies for improving glycemic control: effective use of glucose monitoring. Am. J. Med.118(9A), 275–325 (2005).
   Google Scholar
• Levine DM, Green LW, Deeds SG et al. Health education for hypertensive patients. JAMA241, 1700–1703 (1979).
   PubMed Web of Science ®Google Scholar
• Morisky DE, Levine DM, Green LW et al. Five-year blood pressure control and mortality following health education for hypertensive patients. Am. J. Public Health73, 153–162 (1983).
   PubMed Web of Science ®Google Scholar
• Lerman I. Adherence to treatment: the key for avoiding long-term complications of diabetes. Arch. Med. Res.36, 300–306 (2005).
   PubMed Web of Science ®Google Scholar
• Ciechanowski PS, Katon WJ, Russo JE. The patient-provider relationship: attachment theory and adherence to treatment in diabetes. Am. J. Psychiatry158(1), 29–35 (2001).
   PubMed Web of Science ®Google Scholar
• Faulkner MA, Wadibia C, Hilleman DE. Impact of counseling on compliance and effectiveness of combination lipid-lowering therapy in patients undergoing coronary artery revascularization: a randomized, controlled trial. Pharmacotherapy20(4), 410–416 (2000).
   PubMed Web of Science ®Google Scholar
• Ogedegbe G, Harrison M, Robbins L, Mancuso CA, Allegrante JP. Barriers and facilitators of medication adherence in hypertensive African–Americans: a qualitative study. Ethn. Dis.14, 3–12 (2004).
   PubMed Web of Science ®Google Scholar
• Morisky DE, Green LW, Levine DW. Concurrent and predictive validity of a self-reported measure of medical adherence. Medical Care24, 67–74 (1986).
   PubMed Web of Science ®Google Scholar
• Ward HJ, Morisky DE, Lees NB, Fong R. A clinica and community-based approach to hypertension control for an underserved minority population: design and methods. AJH13, 177–183 (2000).
   Google Scholar
• van der ven NCW, Hogenelst MHE, Tromp-Wever AME et al. Short-term effects of cognitive behavioural group training (CBGT) in adult Type 1 diabetes patietns in prolonged poor glycaemic control. A randomized controlled trial. Diabet. Med.22, 1619–1623 (2005).
   PubMed Web of Science ®Google Scholar
• Snoek FJ, van der ven NCW, Lubach CH et al. Effects of cognitive behavioural group training (CBGT) in adult patients with poorly controlled insulin-dependent (Type 1) diabetes: a pilot study. Patient Educ. Couns.45, 143–148 (2001).
   PubMed Web of Science ®Google Scholar
• McDonald HP, Garg AX, Haynes RB. Interventions to enhance patient adherence to medication prescriptions. JAMA288, 2868–2879 (2002).
   PubMed Web of Science ®Google Scholar